🎉 M&A multiples are live!
Check it out!

Protalix Valuation Multiples

Discover revenue and EBITDA valuation multiples for Protalix and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

Protalix Overview

About Protalix

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.


Founded

1992

HQ

United States of America
Employees

208

Website

protalix.com

Financials

LTM Revenue $61.0M

LTM EBITDA n/a

EV

$143M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Protalix Financials

Protalix has a last 12-month revenue of $61.0M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Protalix achieved revenue of $65.5M and an EBITDA of $12.9M.

Protalix expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Protalix valuation multiples based on analyst estimates

Protalix P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $65.5M $53.9M XXX XXX XXX
Gross Profit $22.0M $28.0M XXX XXX XXX
Gross Margin 34% 52% XXX XXX XXX
EBITDA $12.9M n/a XXX XXX XXX
EBITDA Margin 20% NaN% XXX XXX XXX
Net Profit -$27.6M -$14.9M XXX XXX XXX
Net Margin -42% -28% XXX XXX XXX
Net Debt n/a $11.1M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Protalix Stock Performance

As of March 14, 2025, Protalix's stock price is $2.

Protalix has current market cap of $165M, and EV of $143M.

See Protalix trading valuation data

Protalix Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$143M $165M XXX XXX XXX XXX $0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Protalix Valuation Multiples

As of March 14, 2025, Protalix has market cap of $165M and EV of $143M.

Protalix's trades at 2.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Protalix's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Protalix and 10K+ public comps

Protalix Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $143M XXX XXX XXX
EV/Revenue 2.7x XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E 135.0x XXX XXX XXX
P/E/Growth 0.2x XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Protalix Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Protalix Valuation Multiples

Protalix's NTM/LTM revenue growth is 61%

Protalix's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Protalix's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Protalix's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Protalix and other 10K+ public comps

Protalix Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -18% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 26% XXX XXX XXX XXX
Opex to Revenue 49% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Protalix Public Comps

See public comps and valuation multiples for Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Protalix M&A and Investment Activity

Protalix acquired  XXX companies to date.

Last acquisition by Protalix was  XXXXXXXX, XXXXX XXXXX XXXXXX . Protalix acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Protalix

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Protalix

When was Protalix founded? Protalix was founded in 1992.
Where is Protalix headquartered? Protalix is headquartered in United States of America.
How many employees does Protalix have? As of today, Protalix has 208 employees.
Who is the CEO of Protalix? Protalix's CEO is Mr. Dror Bashan.
Is Protalix publicy listed? Yes, Protalix is a public company listed on ASE.
What is the stock symbol of Protalix? Protalix trades under PLX ticker.
When did Protalix go public? Protalix went public in 2007.
Who are competitors of Protalix? Similar companies to Protalix include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Protalix? Protalix's current market cap is $165M
What is the current revenue of Protalix? Protalix's last 12-month revenue is $61.0M.
What is the current EV/Revenue multiple of Protalix? Current revenue multiple of Protalix is 2.3x.
What is the current revenue growth of Protalix? Protalix revenue growth between 2023 and 2024 was -18%.
Is Protalix profitable? Yes, Protalix is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.